Is DXCM Stock Undervalued?

A comprehensive valuation analysis of Dexcom Inc (DXCM) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated April 15, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

11301042106.3% upside potential

Based on our analysis, Dexcom Inc appears to be potentially undervalued at the current price of $62.95. Our fair value estimate of $7114006068.85 suggests upside potential of approximately 11301042106.3%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing DXCM relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

30.20

High

P/B Ratio

8.97

High

P/S Ratio

5.28

High

EV/EBITDA

17.69

High

Understanding the Metrics

P/E Ratio: At 30.20x earnings, DXCM is trading above the typical market average of 15-20x.
P/B Ratio: A P/B of 8.97 means investors pay $8.97 for every $1 of book value.
P/S Ratio: The price-to-sales ratio of 5.28 indicates how much investors value each dollar of revenue.
EV/EBITDA: This ratio of 17.69 helps compare DXCM to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Dexcom Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$62.95

Fair Value Estimate

$7114006068.85

Implied Return+11301042106.3%

Our DCF model suggests DXCM may be undervalued by approximately 11301042106.3%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Analyst Price Targets

Wall Street analysts provide price targets based on their fundamental research and models. Let's see how the consensus view compares to the current price.

Current Price

$62.95

→

Analyst Target

$87.08

Implied Upside38.3%

The consensus analyst price target of $87.08 suggests 38.3% upside potential from current levels. Analysts appear optimistic about the stock's prospects.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Dexcom Inc (DXCM) appears to be undervalued at $62.95. With a fair value estimate of $7114006068.85, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.